Literature DB >> 25972496

The Strategic Use of Antiretrovirals to Prevent HIV Infection: A Converging Agenda.

Rachel Baggaley1, Meg Doherty1, Andrew Ball1, Nathan Ford1, Gottfried Hirnschall1.   

Abstract

There is a clear convergence toward an overarching strategic use of antiretroviral drugs to prevent human immunodeficiency virus (HIV) infection. Four interventions-immediate antiretroviral therapy (ART) for the infected partner in a serodiscordant couple, preexposure prophylaxis (PrEP), prevention of mother-to-child transmission (PMTCT), and postexposure prophylaxis (PEP)-are all strongly recommended by the World Health Organization as effective ways to prevent HIV infection. For HIV-infected individuals, ART to protect an HIV-uninfected partner and PMTCT are both part of an expanding list of recommendations for starting ART immediately to both treat and prevent HIV infection. For HIV-uninfected individuals, PrEP and PEP are increasingly being seen as related interventions, and there are compelling reasons to consider the provision of PEP as a potential gateway to PrEP. The effectiveness of each of these interventions depends on overcoming barriers to seeking services, adequate community understanding and engagement, high levels of access and uptake of services including HIV testing and counselling, and high levels of adherence.
© The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  HIV/AIDS; PMTCT; antiretroviral therapy; postexposure prophylaxis; preexposure prophylaxis

Mesh:

Substances:

Year:  2015        PMID: 25972496     DOI: 10.1093/cid/civ091

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  6 in total

1.  Intradermal HIV-1 DNA Immunization Using Needle-Free Zetajet Injection Followed by HIV-Modified Vaccinia Virus Ankara Vaccination Is Safe and Immunogenic in Mozambican Young Adults: A Phase I Randomized Controlled Trial.

Authors:  Edna Omar Viegas; Nelson Tembe; Charlotta Nilsson; Bindiya Meggi; Cremildo Maueia; Orvalho Augusto; Richard Stout; Gabriella Scarlatti; Guido Ferrari; Patricia L Earl; Britta Wahren; Sören Andersson; Merlin L Robb; Nafissa Osman; Gunnel Biberfeld; Ilesh Jani; Eric Sandström
Journal:  AIDS Res Hum Retroviruses       Date:  2017-11-27       Impact factor: 2.205

2.  Adverse effects of antiretroviral therapy in pregnant women infected with HIV in Brazil from 2000 to 2015: a cohort study.

Authors:  Adriane M Delicio; Giuliane J Lajos; Eliana Amaral; Fabia Lopes; Fernanda Cavichiolli; Isabeli Myioshi; Helaine Milanez
Journal:  BMC Infect Dis       Date:  2018-09-27       Impact factor: 3.090

3.  "Is it making any difference?" A qualitative study examining the treatment-taking experiences of asymptomatic people living with HIV in the context of Treat-all in Eswatini.

Authors:  Shona Horter; Alison Wringe; Zanele Thabede; Velibanti Dlamini; Bernhard Kerschberger; Munyaradzi Pasipamire; Nomthandazo Lukhele; Barbara Rusch; Janet Seeley
Journal:  J Int AIDS Soc       Date:  2019-01       Impact factor: 5.396

4.  Investigation of prevention of mother to child HIV transmission program from 2011 to 2017 in Suzhou, China.

Authors:  Tian Gong; Huiying Wang; Xiuyu He; Juning Liu; Qianlan Wu; Jing Wang
Journal:  Sci Rep       Date:  2018-12-24       Impact factor: 4.379

5.  Adverse effects in children exposed to maternal HIV and antiretroviral therapy during pregnancy in Brazil: a cohort study.

Authors:  Adriane M Delicio; Giuliane J Lajos; Eliana Amaral; Fernanda Cavichiolli; Marina Polydoro; Helaine Milanez
Journal:  Reprod Health       Date:  2018-05-10       Impact factor: 3.223

6.  Characterisation of a highly potent and near pan-neutralising anti-HIV monoclonal antibody expressed in tobacco plants.

Authors:  Catherine M Moore; Melanie Grandits; Clemens Grünwald-Gruber; Friedrich Altmann; Maria Kotouckova; Audrey Y-H Teh; Julian K-C Ma
Journal:  Retrovirology       Date:  2021-06-28       Impact factor: 4.602

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.